BioPorto A/S

As of June 30, 2026, BioPorto A/S carries a market capitalization of 534.70M, placing it among publicly traded companies globally. Its enterprise value stands at 466.09M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

BioPorto A/S's next confirmed earnings release is scheduled for November 19, 2026.

As of June 30, 2026, BioPorto A/S has 495.10M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 12.93, and the price-to-book ratio stands at 6.49.

These figures are as of June 30, 2026. The EV/Sales ratio of 11.79 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 466.09M versus a market cap of 534.70M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, BioPorto A/S maintains a current ratio of 4.09, meaning it holds 4.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.08, indicating elevated leverage, while an interest coverage ratio of -20.81 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, BioPorto A/S posted a negative return on equity (ROE) of -30.24, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -20.36, reflecting losses generated across the asset base. The company generates approximately 840,893.62 in revenue per employee across its workforce of 47.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.79 indicates how many times BioPorto A/S sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, BioPorto A/S recorded an income tax benefit of -3.23M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -21.96M and -18.73M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, BioPorto A/S's stock has declined approximately 18.76% over the past 52 weeks. The 50-day moving average sits at 1.13, while the 200-day moving average is 1.08.

Over the twelve months ended June 30, 2026, BioPorto A/S generated 39.52M in revenue and converted that into -18.73M in net income, yielding earnings per share of -0.04. EBITDA reached -18.67M, while operating income came in at -20.51M.

As of June 30, 2026, BioPorto A/S holds 74.44M in cash and equivalents against 5.83M in total debt, resulting in a net debt position of -74.44M. Total book value stands at 82.43M, with working capital of 75.12M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, BioPorto A/S posted a gross margin of 75.33, reflecting its pricing power and cost economics. The operating margin of -51.90 and net profit margin of -47.39 provide insight into operational efficiency.

BioPorto A/S's most recent stock split took place on June 1, 2023 with a 629:654 split ratio.

As of June 30, 2026, BioPorto A/S has an Altman Z-Score of 7.22, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.